Neuraxpharm Group has entered into a definitive agreement to acquire two product portfolios for CNS disorders, pain and vascular diseases from Sanofi.
With the upcoming acquisition, Neuraxpharm will strengthen its position as a leading European specialty pharmaceutical company focused on CNS. The well-established products that Neuraxpharm will acquire are marketed globally in more than 50 countries.
The first portfolio combines 15 products addressing CNS disorders and ranging across psychiatry and neurology. The second portfolio includes two products in pain and vascular diseases. Following the acquisition of these new portfolios, Neuraxpharm’s annual gross sales will be around EUR 0.6 billion.
The products benefit patients across a large spectrum of diseases including depression, anxiety, psychosis, alcohol dependence, myasthenia gravis and Parkinson disease. The CNS portfolio notably includes Nozinan, Tranxene, Tiapridal, Dogmatil and Largactil. The pain and vascular portfolio includes Topalgic and Trental.
Combined, both portfolios include 17 molecules representing 38 brands. These global brands will further solidify Neuraxpharm’s position as a leading CNS pharmaceutical company in Europe and increase the company’s global footprint and business.
Dr Jörg-Thomas Dierks, CEO of Neuraxpharm, said: “There is significant growth potential in the pharmaceutical sector, especially in the CNS market driven by an ageing population and an increasing awareness of mental health. This phenomenon is a global trend. With the upcoming acquisition, we will not only strengthen our presence in Europe, but also lay the ground for further expanding our international presence.”
